Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies

References

• Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001;50:884–897. doi:10.1016/S0006-3223(01)01303-811743943
   PubMed Web of Science ®Google Scholar
• Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68(Suppl 14):27–30.
   PubMed Web of Science ®Google Scholar
• Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17:325–351. doi:10.1093/schbul/17.2.3251679255
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 2013;148:117–121. doi:10.1016/j.schres.2013.05.01623756298
   PubMed Web of Science ®Google Scholar
• Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 1997;28:199–206. doi:10.1016/S0920-9964(97)00131-X9468354
   PubMed Web of Science ®Google Scholar
• Emsley R, Nuamah I, Hough D, Gopal S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res. 2012;138:29–34. doi:10.1016/j.schres.2012.02.03022446143
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Alvir JM, Koreen A, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996;14(3 Suppl):13S–21S. doi:10.1016/0893-133X(95)00200-W8866739
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Liu-Seifert H, Kulkarni PM, et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry. 2009;70:990–996.  doi: 10.4088/JCP.08m04221.19497244
   PubMed Web of Science ®Google Scholar
• Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67:1542–1550. doi:10.4088/JCP.v67n100817107245
   PubMed Web of Science ®Google Scholar
• Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry. 2006;67(Suppl 5):9–14.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115:260–267. doi:10.1111/j.1600-0447.2006.00982.x17355516
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241–247.10078501
   PubMed Web of Science ®Google Scholar
• Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus panel for optimizing pharmacologic treatment of psychotic D. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(Suppl 12):5–19.
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381–389. 12065741
   PubMed Web of Science ®Google Scholar
• Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400–1411. doi:10.1038/sj.npp.130020312784105
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73:617–624. doi:10.4088/JCP.11m0753022697189
   PubMed Web of Science ®Google Scholar
• Abilify Maintena US (aripiprazole). Full Prescribing Information, Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan 3 2018 Available from: https://www.otsuka-us.com/media/static/Abilify-M-PI.pdf?_ga=2.209465937.277566499.1550008963-1474538728.1550008963. Accessed 212, 2019.
   Google Scholar
• Orsolini L, Tomasetti C, Valchera A, et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016;15:1329–1347. doi:10.1080/14740338.2016.120147527347638
   PubMed Web of Science ®Google Scholar
• Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. New York, NY: Cambridge University Press; 2013.
   Google Scholar
• Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18:251–267. doi:10.2165/00023210-200418040-0000515015905
   PubMed Web of Science ®Google Scholar
• Bishara D. Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2010;6:561–572. doi:10.2147/NDT.S850520856919
   PubMed Web of Science ®Google Scholar
• De Berardis D, Fornaro M, Serroni N, et al. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Recent Pat Endocr Metab Immune Drug Discov. 2014;8:30–37. doi:10.2174/187221480766613122912570024372345
   PubMedGoogle Scholar
• Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205:135–144. doi:10.1192/bjp.bp.113.13421324925984
   PubMed Web of Science ®Google Scholar
• Peters-Strickland T, Baker RA, McQuade RD, et al. Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. NPJ Schizophr. 2015;1:15039. doi:10.1038/npjschz.2015.3927336044
   PubMedGoogle Scholar
• Kane JM, Sanchez R, Zhao J, et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ. 2013;16:917–925. doi:10.3111/13696998.2013.80441123663091
   PubMedGoogle Scholar
• Kane JM, Zhao C, Johnson BR, et al. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ. 2015;18:145–154. doi:10.3111/13696998.2014.97993625347448
   PubMed Web of Science ®Google Scholar
• Peters-Strickland T, Zhao C, Perry PP, et al. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectr. 2016;21:460–465. doi:10.1017/S109285291600036527531181
   PubMed Web of Science ®Google Scholar
• Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75:1254–1260. doi:10.4088/JCP.14m0916825188501
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276. doi:10.1093/schbul/13.2.2613616518
   PubMed Web of Science ®Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28–37.
   PubMedGoogle Scholar
• Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441–449. doi:10.1176/appi.ajp.162.3.44115741458
   PubMed Web of Science ®Google Scholar
• Ismail Z, Peters-Strickland T, Miguelez M, et al. Aripiprazole once-monthly in the treatment of acute psychotic episodes in schizophrenia: post hoc analysis of positive and negative syndrome scale marder factor scores. J Clin Psychopharmacol. 2017;37:347–350. doi:10.1097/JCP.000000000000071028383362
   PubMed Web of Science ®Google Scholar
• Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry. 2004;19:21–26. doi:10.1016/j.eurpsy.2003.10.00414969777
   PubMed Web of Science ®Google Scholar
• Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65:932–939. doi:10.4088/JCP.v65n070915291682
   PubMed Web of Science ®Google Scholar